Waters(US:WAT) Prnewswire·2026-02-09 11:30Core Insights - Waters Corporation reported strong financial results for Q4 and full-year 2025, with significant growth in both GAAP and non-GAAP earnings per share (EPS) [1][2] - The company anticipates continued momentum into 2026, driven by instrument replacement cycles and innovative product offerings [1][2] Financial Performance Fourth Quarter 2025 - GAAP EPS was $3.77, while non-GAAP EPS increased by 10% to $4.53 [1] - Sales reached $932 million, a 7% increase as reported and 6% in constant currency compared to Q4 2024 [1] - Instrument sales grew by 3%, with chemistry sales increasing by 12% in constant currency [1][2] - Recurring revenues rose by 10% as reported and 9% in constant currency [1] Full-Year 2025 - GAAP EPS for the year was $10.76, and non-GAAP EPS grew by 11% to $13.13 [1] - Total sales were $3,165 million, reflecting a 7% increase as reported and in constant currency compared to 2024 [1] - Recurring revenue grew by 8% in constant currency, with chemistry leading at 12% growth [1][2] Market Segments - Pharmaceutical sales increased by 9% for the year, while industrial sales grew by 6% [1][2] - Academic and government market sales remained flat, with a slight decrease in constant currency [1] - Geographically, sales in Asia increased by 7% as reported and 13% in constant currency, while Europe saw a 10% increase as reported and 5% in constant currency [1][2] Future Guidance Full-Year 2026 - The company expects organic constant currency revenue growth of 5.5% to 7.0% [1] - Total reported revenue is projected to be between $6.405 billion and $6.455 billion, including contributions from acquired businesses [1] - Non-GAAP EPS is anticipated to be in the range of $14.30 to $14.50, representing year-over-year growth of approximately 8.9% to 10.4% [1] First Quarter 2026 - Organic constant currency revenue growth is expected to be between 7.0% and 9.0% [1] - Total reported revenue for Q1 2026 is projected to be between $1.198 billion and $1.211 billion [1]